Premium
Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years
Author(s) -
Hughes A. J.,
Bishop Susan,
Kleedorfer Birgit,
Turjanski Nora,
Fernandez W.,
Lees A. J.,
Stern G. M.
Publication year - 1993
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870080208
Subject(s) - apomorphine , domperidone , medicine , parkinson's disease , levodopa , dopamine agonist , anesthesia , dopaminergic , dopamine receptor , agonist , refractory (planetary science) , disease , dopamine , receptor , physics , astrobiology
Abstract Subcutaneous apomorphine, administered by continuous waking‐day infusion with boluses, or by repeated intermittent injection, was given to 71 parkinsonian patients with severe refractory levodopa related on‐off flutuations for 1–5 years. A mean reduction in daily off period time of ∼50% was maintained, and the incidence of neuropsychiatric toxicity remained low on long‐term follow‐up. No clinically significant tolerance or loss of therapeutic effect was seen, although increasingly severe on‐phase dyskinesias and postural instability marred the long‐term therapeutic response in many patients. Despite these drawbacks, apomorphine, when combined with the peripheral dopamine receptor agonist domperidone, represents a significant therapeutic advance in the management of late‐stage Parkinson's disease and should certainly be considered before experimental implantation procedures.